WO2011034582A3 - Anticorps anti-vih-1 - Google Patents

Anticorps anti-vih-1 Download PDF

Info

Publication number
WO2011034582A3
WO2011034582A3 PCT/US2010/002515 US2010002515W WO2011034582A3 WO 2011034582 A3 WO2011034582 A3 WO 2011034582A3 US 2010002515 W US2010002515 W US 2010002515W WO 2011034582 A3 WO2011034582 A3 WO 2011034582A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
antibodies
relates
present
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/002515
Other languages
English (en)
Other versions
WO2011034582A2 (fr
Inventor
Barton F. Haynes
Georgia Tomaras
Shaunna Shen
Dimiter S. Dimitrov
Zhongyu Zhu
Kwan-Ki Hwang
Nicholas Chiorazzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Duke University
US Department of Health and Human Services
Original Assignee
Feinstein Institutes for Medical Research
Duke University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feinstein Institutes for Medical Research, Duke University, US Department of Health and Human Services filed Critical Feinstein Institutes for Medical Research
Priority to JP2012529742A priority Critical patent/JP2013505236A/ja
Priority to EP10817555A priority patent/EP2477658A2/fr
Priority to CA2774446A priority patent/CA2774446A1/fr
Priority to AU2010296058A priority patent/AU2010296058A1/en
Publication of WO2011034582A2 publication Critical patent/WO2011034582A2/fr
Publication of WO2011034582A3 publication Critical patent/WO2011034582A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne, en général, des anticorps spécifiques de VIH-1, et en particulier des anticorps spécifiques de VIH-1 à neutralisation large qui ciblent la région externe proximale de la membrane (MPER) de gp41. La présente invention concerne également un système de culture cellulaire, plus spécifiquement un procédé pour immortaliser des lymphocytes B de leucémie lymphoïde chronique et un procédé d'isolement d'anticorps antiviraux à partir de clones de telles cellules.
PCT/US2010/002515 2009-09-16 2010-09-16 Anticorps anti-vih-1 Ceased WO2011034582A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012529742A JP2013505236A (ja) 2009-09-16 2010-09-16 Ｈｉｖ−１抗体
EP10817555A EP2477658A2 (fr) 2009-09-16 2010-09-16 Anticorps anti-vih-1
CA2774446A CA2774446A1 (fr) 2009-09-16 2010-09-16 Anticorps anti-vih-1
AU2010296058A AU2010296058A1 (en) 2009-09-16 2010-09-16 HIV-1 antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27234909P 2009-09-16 2009-09-16
US61/272,349 2009-09-16
US24879609P 2009-10-05 2009-10-05
US61/248,796 2009-10-05

Publications (2)

Publication Number Publication Date
WO2011034582A2 WO2011034582A2 (fr) 2011-03-24
WO2011034582A3 true WO2011034582A3 (fr) 2011-09-15

Family

ID=43759219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002515 Ceased WO2011034582A2 (fr) 2009-09-16 2010-09-16 Anticorps anti-vih-1

Country Status (5)

Country Link
EP (1) EP2477658A2 (fr)
JP (1) JP2013505236A (fr)
AU (1) AU2010296058A1 (fr)
CA (1) CA2774446A1 (fr)
WO (1) WO2011034582A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3271022A4 (fr) * 2015-03-19 2018-10-31 Duke University Anticorps neutralisant le vih-1 et leurs utilisations
US11071783B2 (en) 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
BR112019013468A8 (pt) 2016-12-27 2022-11-22 Univ Rockefeller Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
DK4257600T3 (da) 2018-07-03 2025-05-26 Gilead Sciences Inc Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
JP7518286B2 (ja) 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3259040A1 (fr) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci
WO2024097957A1 (fr) * 2022-11-03 2024-05-10 Duke University Nouveaux anticorps contre le vih et leurs procédés de fabrication et d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081723A1 (en) * 1995-06-07 2002-06-27 Peter Brams Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and theraputic use thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006110831A2 (fr) * 2005-04-12 2006-10-19 Duke University Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081723A1 (en) * 1995-06-07 2002-06-27 Peter Brams Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and theraputic use thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006110831A2 (fr) * 2005-04-12 2006-10-19 Duke University Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VIDAR WENDEL-HANSEN ET AL.: "Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines.", LEUKEMIA, vol. 8, no. 3, 1994, pages 476 - 484, XP008154323 *
XIAOYING SHEN ET AL.: "In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.", JOURNAL OF VIROLOGY, vol. 83, no. 8, April 2009 (2009-04-01), pages 3617 - 3625, XP008154322 *

Also Published As

Publication number Publication date
CA2774446A1 (fr) 2011-03-24
WO2011034582A2 (fr) 2011-03-24
AU2010296058A1 (en) 2012-05-03
JP2013505236A (ja) 2013-02-14
EP2477658A2 (fr) 2012-07-25

Similar Documents

Publication Publication Date Title
WO2011034582A3 (fr) Anticorps anti-vih-1
WO2011046623A3 (fr) Anticorps anti-vih-1
WO2008089043A3 (fr) Piles solaires à jonction multiple et procédés et appareils pour la formation de celles-ci
HK1256737A1 (zh) 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群
WO2012166425A3 (fr) Procédés d'amplification du génome total d'une cellule isolée
WO2010088633A3 (fr) Nouvelles lignées cellulaires et procédés
WO2013048068A3 (fr) Procédé de fourniture d'une publicité personnalisée dans un récepteur
WO2012154794A3 (fr) Concentration d'enzymes et dosages
WO2011133722A3 (fr) Composés antiviraux
WO2010089411A3 (fr) Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
EP3778606A3 (fr) Imidazolylimidazoles condensés en tant que composés antiviraux
WO2011056644A3 (fr) Anticorps anti-glp-1r et leurs utilisations
WO2013016468A3 (fr) Compositions et procédés permettant d'améliorer la puissance et la portée d'anticorps anti-vih
WO2011059725A3 (fr) Cellules souches pluripotentes
WO2012102896A3 (fr) Procédés et systèmes d'isolement enzymatique de la lignine et d'autres produits biologiques de plantes herbacées
WO2011133728A3 (fr) Composés antiviraux
WO2011133729A3 (fr) Composés antiviraux
AU2011283590B2 (en) Steam permselective membrane, and method using same for separating steam from mixed gas
EP2671964A4 (fr) Feuille d'acier laminée à froid à haute résistance, ayant une excellente aptitude au traitement et un rapport d'élasticité élevé, et son procédé de fabrication
WO2012057504A3 (fr) Cellule solaire et son procédé de fabrication
WO2012145759A3 (fr) Procédés de production de protéine et compositions associées
WO2011106100A3 (fr) Procédé d'induction de la production d'anticorps protecteurs anti-vih-1
WO2012161545A3 (fr) Composition qui favorise l'apoptose ou inhibe la croissance cellulaire comprenant un miarn du virus d'epstein-barr
MX349801B (es) Sustratos de enzimas de ácido nucleico.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10817555

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2012529742

Country of ref document: JP

Ref document number: 2774446

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010817555

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010296058

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010296058

Country of ref document: AU

Date of ref document: 20100916

Kind code of ref document: A